Cantargia Confident About Nadunolimab’s Prospects For Pancreatic Cancer
Swedish Biotech Raises Funds To Advance IL1RAP Inhibitor
Executive Summary
The selection of nadulonimab by the Pancreatic Cancer Action Network for its adaptive clinical trial is a strong validation of the Stockholm-based firm's compound, which is also being evaluated for lung cancer.